Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

242 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
S1-Guideline Sebaceous Carcinoma.
Utikal J, Nagel P, Müller V, Becker JC, Dippel E, Frisman A, Gschnell M, Griewank K, Hadaschik E, Helbig D, Hillen U, Leiter U, Pföhler C, Krönig L, Ziemer M, Ugurel S. Utikal J, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2024 May;22(5):730-747. doi: 10.1111/ddg.15405. Epub 2024 Apr 28. J Dtsch Dermatol Ges. 2024. PMID: 38679790
S1-guideline cutaneous and subcutaneous leiomyosarcoma.
Helbig D, Dippel E, Erdmann M, Frisman A, Kage P, Leiter U, Mentzel T, Seidel C, Weishaupt C, Ziemer M, Ugurel S. Helbig D, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2023 May;21(5):555-563. doi: 10.1111/ddg.14989. Epub 2023 Mar 31. J Dtsch Dermatol Ges. 2023. PMID: 36999582
S1-Leitlinie dermales und subkutanes Leiomyosarkom.
Helbig D, Dippel E, Erdmann M, Frisman A, Kage P, Leiter U, Mentzel T, Seidel C, Weishaupt C, Ziemer M, Ugurel S. Helbig D, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2023 May;21(5):555-564. doi: 10.1111/ddg.14989_g. J Dtsch Dermatol Ges. 2023. PMID: 37183752
Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial.
Becker JC, Ugurel S, Leiter U, Meier F, Gutzmer R, Haferkamp S, Zimmer L, Livingstone E, Eigentler TK, Hauschild A, Kiecker F, Hassel JC, Mohr P, Fluck M, Thomas I, Garzarolli M, Grimmelmann I, Drexler K, Spillner AN, Eckhardt S, Schadendorf D; DeCOG. Becker JC, et al. Lancet. 2023 Sep 2;402(10404):798-808. doi: 10.1016/S0140-6736(23)00769-9. Epub 2023 Jul 11. Lancet. 2023. PMID: 37451295 Clinical Trial.
Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.
Livingstone E, Gogas H, Kandolf-Sekulovic L, Meier F, Eigentler TK, Ziemer M, Terheyden PAM, Gesierich AH, Herbst RA, Kähler KC, Ziogas DC, Mijuskovic Z, Garzarolli M, Garbe C, Roesch A, Ugurel S, Gutzmer R, Grob JJ, Kiecker F, Utikal J, Windemuth-Kieselbach C, Eckhardt S, Zimmer L, Schadendorf D. Livingstone E, et al. Among authors: ziemer m. Eur J Cancer. 2023 Sep;190:112941. doi: 10.1016/j.ejca.2023.112941. Epub 2023 Jun 15. Eur J Cancer. 2023. PMID: 37482012 Clinical Trial.
Health-related quality of life and its influencing factors in patients with primary cutaneous B-cell lymphomas: A multicentric study in 100 patients.
Schirren AEC, Albrecht JD, Melchers S, Weiß C, Büttner S, Dippel E, Gosmann J, Jonak C, Klemke CD, Laturnus-Chang M, Livingstone E, Mitteldorf C, Schummer P, Stadler R, Stranzenbach R, Weyer-Fahlbusch SS, Wobser M, Ziemer M, Nicolay JP. Schirren AEC, et al. Among authors: ziemer m. J Eur Acad Dermatol Venereol. 2024 May;38(5):954-966. doi: 10.1111/jdv.19799. Epub 2024 Jan 26. J Eur Acad Dermatol Venereol. 2024. PMID: 38279594
[No title available]
[No authors listed] [No authors listed] PMID: 38730519
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 1: Diagnosis, initial management, and immunomodulating systemic therapy.
Heuer R, Paulmann M, Annecke T, Behr B, Boch K, Boos AM, Brockow K, French LE, Gille J, Gundlach V, Hartmann B, Höger P, Hofmann SC, Klein T, Lehnhardt M, Liß Y, Maier P, Mandel P, Marathovouniotis N, Marlok F, Mittelviefhaus H, Pleyer U, Pradeau M, Rall K, Rieg S, Rittner H, Sander F, Schnitzler S, Schut C, Stolle A, Vorobyev A, Wedi B, Weiss J, Zepp M, Ziemer M, Mockenhaupt M, Nast A. Heuer R, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2024 Oct;22(10):1448-1466. doi: 10.1111/ddg.15515. Epub 2024 Sep 23. J Dtsch Dermatol Ges. 2024. PMID: 39314017
S3 guideline: Diagnosis and treatment of epidermal necrolysis (Stevens-Johnson syndrome and toxic epidermal necrolysis) - Part 2: Supportive therapy of EN in the acute and post-acute stages.
Paulmann M, Heuer R, Annecke T, Behr B, Boch K, Boos AM, Brockow K, French LE, Gille J, Gundlach V, Hartmann B, Höger P, Hofmann SC, Klein T, Lehnhardt M, Liß Y, Maier P, Mandel P, Marathovouniotis N, Marlok F, Mittelviefhaus H, Pleyer U, Pradeau M, Rall K, Rieg S, Rittner H, Sander F, Schnitzler S, Schut C, Stolle A, Vorobyev A, Wedi B, Weiss J, Zepp M, Ziemer M, Mockenhaupt M, Nast A. Paulmann M, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2024 Nov;22(11):1576-1593. doi: 10.1111/ddg.15516. Epub 2024 Oct 17. J Dtsch Dermatol Ges. 2024. PMID: 39417754
S1-Leitlinie: Mikroskopisch kontrollierte Chirurgie.
Kofler L, Ziemer M, Andrulis M, Horn D, Kulas P, Kunte C, Müller CSL. Kofler L, et al. Among authors: ziemer m. J Dtsch Dermatol Ges. 2022 Dec;20(12):1663-1675. doi: 10.1111/ddg.14910_g. J Dtsch Dermatol Ges. 2022. PMID: 36508373
242 results